Pr Essand - Elicera Therapeutics CoFounder Officer
Insider
Pr Essand is CoFounder Officer of Elicera Therapeutics AB
| Age | 59 |
| Phone | 46 7 03 31 90 51 |
| Web | https://www.elicera.com |
Elicera Therapeutics Management Efficiency
The company has return on total asset (ROA) of (0.2258) % which means that it has lost $0.2258 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of (0.3883) %, meaning that it generated substantial loss on money invested by shareholders. Elicera Therapeutics' management efficiency ratios could be used to measure how well Elicera Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
| Found 12 records | INSIDER Age | ||
| Karin Agerman | Combigene AB | 50 | |
| Ingvar Karlsson | Idogen AB | 67 | |
| Jan Nilsson | Combigene AB | 74 | |
| Associate Woldbye | Combigene AB | 60 | |
| Peter Ekolind | Combigene AB | 59 | |
| Hanjing Xie | Idogen AB | 53 | |
| Mr MSc | Idogen AB | 61 | |
| Louise Aspenberg | Combigene AB | 47 | |
| Rory Graham | Idogen AB | N/A | |
| Prof MD | Idogen AB | 82 | |
| Pr Kokaia | Combigene AB | 67 | |
| Christina Herder | Idogen AB | 62 | |
Management Performance
| Return On Equity | -0.39 | |||
| Return On Asset | -0.23 |
Elicera Therapeutics Leadership Team
Elected by the shareholders, the Elicera Therapeutics' board of directors comprises two types of representatives: Elicera Therapeutics inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Elicera. The board's role is to monitor Elicera Therapeutics' management team and ensure that shareholders' interests are well served. Elicera Therapeutics' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Elicera Therapeutics' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Jamal MSc, CEO CoFounder | ||
| Pr Essand, CoFounder Officer | ||
| Di Yu, CoFounder Operations | ||
| Ingvar Karlsson, Chief Officer |
Elicera Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Elicera Therapeutics a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.39 | |||
| Return On Asset | -0.23 | |||
| Operating Margin | (23.30) % | |||
| Current Valuation | 42.8 M | |||
| Shares Outstanding | 19.78 M | |||
| Shares Owned By Insiders | 62.87 % | |||
| Price To Book | 2.21 X | |||
| Price To Sales | 106.48 X | |||
| Revenue | 587 | |||
| Gross Profit | 587 |
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Elicera Stock Analysis
When running Elicera Therapeutics' price analysis, check to measure Elicera Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Elicera Therapeutics is operating at the current time. Most of Elicera Therapeutics' value examination focuses on studying past and present price action to predict the probability of Elicera Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Elicera Therapeutics' price. Additionally, you may evaluate how the addition of Elicera Therapeutics to your portfolios can decrease your overall portfolio volatility.